IND Swift Laboratories Ltd
Mr. Rishav Mehta is the Executive Director of the Ind-Swift Group. While placed at strategic level, Mr. Mehta involves himself at tactical layers for capacity building of organization and to ensure that Strategic goals are well aligned with the functional competencies.
This person is not in any offices
IND Swift Laboratories Ltd
Ind-Swift Laboratories Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs). The Company operates through the bulk drugs and pharmaceuticals segment. The Company has a product portfolio of approximately 50 products across approximately 15 therapeutic segments. It manufactures Clarithromycin powder/granules, Atorvastatin Calcium Crystalline, Roxithromycin and Nitazoxanide. It also manufactures Nateglinide, Dutasteride, Moxifloxacin and Imatinib Mesylate. The Company offers products for various therapeutic categories, such as macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsyhotic, bone resorption inhibitor, hyperparathyrodism, antineoplastic, treatment of premature ejaculation and nootropic. Its research and development projects include Crams for API Development Medicinal Chemistry development for various discovery projects. The Company also operates a menthol and mint products manufacturing facility.